Shanghai Kaibao Pharmaceutical Co., Ltd. (300039) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Shanghai Kaibao Pharmaceutical Co., Ltd.

Why is Shanghai Kaibao Pharmaceutical Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of 1.64% and Operating profit at 23.85% over the last 5 years

With a fall in Net Profit of -23.05%, the company declared Very Negative results in Mar 26

The company has declared negative results for the last 6 consecutive quarters
INTEREST(HY) At CNY 0.06 MM has Grown at 37.35%
OPERATING CASH FLOW(Y) Lowest at CNY 291.47 MM
NET SALES(Q) At CNY 283.25 MM has Fallen at -29.3%

Below par performance in long term as well as near term

Along with generating -27.80% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Shanghai Kaibao Pharmaceutical Co., Ltd. for you?

Medium Risk, Low Return

Absolute

Risk Adjusted

Volatility

Shanghai Kaibao Pharmaceutical Co., Ltd.

-13.26%

-0.75

26.57%

China Shanghai Composite

3.23%

1.20

14.07%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

1.64%

EBIT Growth (5y)

23.85%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.21

Sales to Capital Employed (avg)

0.34

Tax Ratio

12.57%

Dividend Payout Ratio

48.82%

Pledged Shares

Institutional Holding

ROCE (avg)

8.27%

ROE (avg)

6.40%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.93

EV to EBIT

13.70

EV to EBITDA

12.32

EV to Capital Employed

0.92

EV to Sales

3.17

PEG Ratio

Dividend Yield

3.11%

ROCE (Latest)

6.68%

ROE (Latest)

5.70%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Bullish

Bearish

Moving Averages

Bearish (Daily)

KST

Bullish

Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

1What is working for the Company

RAW MATERIAL COST(Y)

Fallen by 1% (YoY

-32What is not working for the Company

INTEREST(HY)

At CNY 0.08 MM has Grown at 79.16%

OPERATING CASH FLOW(Y)

Lowest at CNY 282.76 MM

NET PROFIT(9M)

At CNY 205.62 MM has Grown at -26.38%

ROCE(HY)

Lowest at 6.05%

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.07 times

INTEREST COVERAGE RATIO(Q)

Lowest at 110,070.03

NET SALES(Q)

Lowest at CNY 179.67 MM

OPERATING PROFIT(Q)

Lowest at CNY 34.98 MM

OPERATING PROFIT MARGIN(Q)

Lowest at 19.47 %

EPS(Q)

Lowest at CNY 0.04

Here's what is working for Shanghai Kaibao Pharmaceutical Co., Ltd.

Raw Material Cost

Fallen by 1% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Shanghai Kaibao Pharmaceutical Co., Ltd.

Interest

At CNY 0.08 MM has Grown at 79.16%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Interest Coverage Ratio

Lowest at 110,070.03

in the last five periods

MOJO Watch

The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Inventory Turnover Ratio

Lowest at 1.07 times and Fallen

In each half year in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Net Profit

At CNY 205.62 MM has Grown at -26.38%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is negative

Net Profit (CNY MM)

Operating Cash Flow

Lowest at CNY 282.76 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Net Sales

Lowest at CNY 179.67 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (CNY MM)

Net Sales

Fallen at -11.93%

Year on Year (YoY)

MOJO Watch

Near term sales trend is negative

Net Sales (CNY MM)

Operating Profit

Lowest at CNY 34.98 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (CNY MM)

Operating Profit Margin

Lowest at 19.47 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

EPS

Lowest at CNY 0.04

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (CNY)

Non Operating Income

Highest at CNY 0.27 MM

in the last five periods

MOJO Watch

Increased income from non business activities may not be sustainable

Non Operating income